Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.55% | -26.54% | -45.49% | -108.36% | -207.05% |
| Total Depreciation and Amortization | -23.37% | -15.66% | -1.87% | 44.98% | 127.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 308.46% | 112.30% | 12.11% | 34.04% | -32.97% |
| Change in Net Operating Assets | -157.06% | -113.69% | -131.43% | 216.57% | 1,006.03% |
| Cash from Operations | -12.54% | -34.54% | -64.22% | -78.11% | -142.01% |
| Capital Expenditure | 99.70% | 99.77% | 73.19% | 66.51% | -89.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.58% | 125.17% | 155.61% | 141.52% | 65.92% |
| Cash from Investing | 51.41% | 124.87% | 154.61% | 130.32% | 77.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 48.12% | 15.48% | -4.53% | -59.18% | -136.89% |
| Issuance of Common Stock | 59,564.14% | -65.47% | -99.51% | -99.96% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.90% | 85.87% | 91.51% | 91.51% | 89.16% |
| Cash from Financing | 10,580.07% | -58.12% | -99.94% | -100.39% | -100.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.26% | -55.66% | -186.31% | -200.00% | -197.99% |